Nektar Therapeutics’ (NKTR) “Buy” Rating Reaffirmed at HC Wainwright

Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $185.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 301.89% from the stock’s current price.

Several other equities research analysts have also weighed in on the company. JPMorgan Chase & Co. began coverage on Nektar Therapeutics in a research report on Friday, August 21st. They set a “neutral” rating and a $65.00 price target on the stock. TD Cowen upgraded Nektar Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Canaccord Genuity Group began coverage on Nektar Therapeutics in a research report on Wednesday, July 22nd. They set a “buy” rating and a $153.00 price target on the stock. BTIG Research restated a “buy” rating and set a $178.00 price target on shares of Nektar Therapeutics in a research report on Friday, September 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nektar Therapeutics in a research report on Friday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $138.50.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR traded down $0.96 during mid-day trading on Friday, hitting $46.03. 621,276 shares of the stock traded hands, compared to its average volume of 1,076,158. Nektar Therapeutics has a 52 week low of $33.40 and a 52 week high of $109.00. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -6.89 and a beta of 1.26. The stock has a fifty day moving average price of $70.09 and a 200-day moving average price of $71.25.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.97) by $0.74. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%.The company had revenue of $10.13 million for the quarter, compared to analyst estimates of $10.43 million. As a group, sell-side analysts predict that Nektar Therapeutics will post -8.16 EPS for the current fiscal year.

Insider Buying and Selling

In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the sale, the chief executive officer directly owned 54,627 shares of the company’s stock, valued at approximately $3,932,051.46. The trade was a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. KBC Group NV purchased a new stake in Nektar Therapeutics in the first quarter worth about $52,000. FNY Investment Advisers LLC increased its position in Nektar Therapeutics by 15.8% in the second quarter. FNY Investment Advisers LLC now owns 5,500 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 750 shares in the last quarter. State of Wyoming purchased a new stake in Nektar Therapeutics in the first quarter worth about $67,000. Arizona State Retirement System increased its position in Nektar Therapeutics by 27.3% in the second quarter. Arizona State Retirement System now owns 8,477 shares of the biopharmaceutical company’s stock worth $592,000 after buying an additional 1,816 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in Nektar Therapeutics by 32.5% in the first quarter. Janus Henderson Group PLC now owns 10,729 shares of the biopharmaceutical company’s stock worth $771,000 after buying an additional 2,629 shares in the last quarter. 75.88% of the stock is owned by institutional investors.

Key Headlines Impacting Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and assigned a $185 price target, implying substantial potential upside from the recent trading level. The bullish view reflects confidence in rezpegaldesleukin and Nektar’s broader pipeline.
• Positive Sentiment: New Phase 2b data showed durable treatment benefits in alopecia areata and atopic dermatitis. In alopecia areata, 75% of patients who reached a SALT score of 20 or less maintained that response four months after treatment, while 63% maintained it after six months. Hair regrowth continued during the off-treatment period, supporting the potential for a lasting treatment effect. New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement
• Neutral Sentiment: Nektar has expanded its late-stage development plans, initiating a third Phase 3 study in treatment-experienced atopic dermatitis patients and planning to begin the Phase 3 ZENITH-AA alopecia areata study in early 2027. These milestones improve the long-term opportunity but also highlight that regulatory approval and commercial revenue remain several steps away. Nektar Reports Durable Rezpegaldesleukin Data
• Neutral Sentiment: Earlier biomarker results showed that rezpegaldesleukin affected multiple immune pathways as soon as Week 2, with changes correlating with later clinical improvement. The findings support the drug’s mechanism but are not, by themselves, evidence of approval or commercial success. New Biomarker Data for Rezpegaldesleukin
• Negative Sentiment: Despite the encouraging results, NKTR shares decreased as investors appeared to focus on the data being Phase 2b, the need for additional Phase 3 testing, and uncertainty over how durable the benefits will be across a broad patient population. Elevated options activity has likely amplified the stock’s volatility.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that use the body’s immune system to treat cancer and autoimmune diseases. The company’s research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents.

Nektar’s pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses.